Kanzius Cancer Research ~ Research and Clinical Trials

Biomedical Engineers from UC Davis use Kanzius' Method to Kill Cancer Cells ~

Mon, 18 Jul 2011 12:00:00 -0600

Published July 2011 in IEEE Transactions on Biomedical Engineering

Building on John Kanzius’ vision, a team of biomedical engineers from University of California of Davis have developed a delivery system capable of performing the Kanzius Noninvasive Radiowave Cancer Treatment. This manuscript, A Radio-frequency Coupling Network for Heating of Citrate-coated Gold Nanoparticles for Cancer Therapy: Design and Analysis, published in the IEEE Transactions on Biomedical Engineering (one of the leading research journals in the field of biomedical engineering) demonstrates that cancer cells are killed when incubated with gold nanoparticles (GNPs) and exposed to certain levels of Radiofrequency electromagnetic (RF-EM) fields. DOWNLOAD HERE »

Exciting News from the Kanzius Labs at M.D. Anderson Cancer Center ~

Sun, 01 Aug 2010 12:00:00 -0600

Laboratory Staff and Equipment

Our post-doc from the University of Arizona, Dr. Evan Glazer, completed his work in June 2010 and has returned to Arizona. He was incredibly productive during his two years in the lab and published a number of important papers.

Kanzius team's groundbreaking discovery ~

Fri, 02 Jul 2010 12:00:00 -0600

featured in July issue of Cancer

Cancer, a highly respected journal published by the American Cancer Society, will feature a paper by researchers at the Kanzius lab – Drs. Evan Glazer and Steven Curley.

Exciting News from The Kanzius Labs at MD Anderson ~

Thu, 14 Jan 2010 12:00:00 -0700

Mark Neidig, executive director of the Kanzius Cancer Research Foundation, just returned from several days of meetings and observation with Dr. Steven A. Curley, lead investigator...

Dr. Steven Curley, Update ~

Tue, 23 Jun 2009 12:00:00 -0600

Dr. Steven Curley reports work is progressing at a rapid pace to take the John Kanzius Radio Frequency Cancer Treatment to the next step…clinical trials involving large animals are set to begin as soon as possible.

Dr. Steven Curley, Spring 2009 Update ~

Mon, 02 Mar 2009 12:00:00 -0700

Dr. Steven Curley reports work is progressing at a rapid pace to take the Kanzius Non-invasive Radio Wave Cancer Treatment to the next step…clinical trials involving large animals are set to begin in the near future. Equipment for those trials is now being built by Industrial Sales and Manufacturing, Inc. in Erie, Pennsylvania.

Dr. Steven Curley: Winter 2008/2009 Update ~

Mon, 23 Feb 2009 12:00:00 -0700

I am pleased to report we continue to make excellent progress in our use of the Kanzius radiofrequency field device to treat human cancers. Since the last update, a manuscript has just been accepted in which we prove we can target gold nanoparticles to malignant cells that express a specific type of receptor at the surface of the cell. This leads to increased levels of the gold nanoparticles in the cancer cells.

Participation in Human Trials ~

Mon, 09 Feb 2009 12:00:00 -0700

At this time, we are not accepting, nor wait-listing patients for clinical trials. The Kanzius Cancer Research Foundation will have no formal role in developing lists or procedures regarding human trials. However, we will post all news and research data on this web site as soon as it becomes available.

Kanzius Cancer Research Highlights of 2008 ~

Fri, 12 Dec 2008 12:00:00 -0700

The year began with hope and promise, and ended with a list of major accomplishments, including a research staff that grew from one part time assistant, to 13 full-time medical professionals. All of the items listed below were made possible by your gifts, from $1 to $500,000....each gift makes a difference.

About Clinical Trials ~

Wed, 19 Nov 2008 12:00:00 -0700

Clinical trials are conducted in phases. The trials at each phase have a different purpose, and they help scientists answer different questions:

In Phase I trials, researchers test an experimental drug or treatment in a small group of people (20 to 80) for the first time to evaluate its safety, to determine a safe dosage range, and to identify side effects.